Paper27141007
Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.
Iasonos A and 2 others. Clin Cancer Res, 2016. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. Papers, record 27141007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27141007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers | Major topic |
| Humans | |
| Mutation | |
| Proportional Hazards Models | |
| Risk Assessment | |
| Risk Factors | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| R01 CA137420 | NCI NIH HHS | United States | R01CA137420 | PubMed and NIH | NIH RePORTER |
| R01 CA197402 | NCI NIH HHS | United States | R01CA197402 | PubMed and NIH | NIH RePORTER |
| UL1 TR000457 | NCATS NIH HHS | United States | UL1TR000457 | PubMed and NIH | NIH RePORTER |
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15273082 | Hazard ratio in clinical trials. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/15273082 | PubMed |
| 2 | 26027431 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26027431 | PubMed |
| 3 | 4027319 | Testing for qualitative interactions between treatment effects and patient subsets. | Biometrics | 1985 | https://conductscience.org/library/papers/4027319 | PubMed |
| 4 | 18316791 | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18316791 | PubMed |
| 5 | 18946061 | K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18946061 | PubMed |
| 6 | 20010207 | The hazards of hazard ratios. | Epidemiology | 2010 | https://conductscience.org/library/papers/20010207 | PubMed |
| 7 | 21102529 | Statistical interaction in human genetics: how should we model it if we are looking for biological interaction? | Nat Rev Genet | 2011 | https://conductscience.org/library/papers/21102529 | PubMed |
| 8 | 21107323 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. | Nature | 2010 | https://conductscience.org/library/papers/21107323 | PubMed |
| 9 | 21150212 | The meaning of interaction. | Hum Hered | 2010 | https://conductscience.org/library/papers/21150212 | PubMed |
| 10 | 21337591 | Personalized estimates of breast cancer risk in clinical practice and public health. | Stat Med | 2011 | https://conductscience.org/library/papers/21337591 | PubMed |
| 11 | 21705679 | Risk factor modification and projections of absolute breast cancer risk. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/21705679 | PubMed |
| 12 | 21705680 | The numbers game: the risky business of projecting risk. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/21705680 | PubMed |
| 13 | 21931068 | Helping patients decide: ten steps to better risk communication. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/21931068 | PubMed |
| 14 | 22658127 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658127 | PubMed |
| 15 | 23134356 | Progression of RAS-mutant leukemia during RAF inhibitor treatment. | N Engl J Med | 2012 | https://conductscience.org/library/papers/23134356 | PubMed |
| 16 | 24982461 | Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/24982461 | PubMed |
| 17 | 25452452 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25452452 | PubMed |
| 18 | 6366135 | Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. | J Clin Oncol | 1983 | https://conductscience.org/library/papers/6366135 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39707607 | Genetic variants of FER and SULF1 in the fibroblast-related genes are associated with non-small-cell lung cancer survival. | Int J Cancer | 2025 | https://conductscience.org/library/papers/39707607 | PubMed |
| 36038907 | lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. | J Transl Med | 2022 | https://conductscience.org/library/papers/36038907 | PubMed |
| 34750392 | Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. | Nat Commun | 2021 | https://conductscience.org/library/papers/34750392 | PubMed |
| 28934243 | Time to publication of oncology trials and why some trials are never published. | PLoS One | 2017 | https://conductscience.org/library/papers/28934243 | PubMed |
| 28258415 | Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. | Ann Surg Oncol | 2017 | https://conductscience.org/library/papers/28258415 | PubMed |
| 28254404 | Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. | Contemp Clin Trials | 2017 | https://conductscience.org/library/papers/28254404 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27141007
GET https://conductscience.org/api/papers/v1/27141007/authors